Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD

Respiratory Medicine

Volumn 105, Issue 6, 2011, Pages 892-899

  Jones, Paul W ^a   Mahler, Donald A ^b   Gale, Rupert ^c   Owen, Roger ^c   Kramer, Benjamin ^d  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Dyspnoea; Formoterol; Health status; Indacaterol; Salmeterol; Tiotropium

Indexed keywords

BRONCHODILATING AGENT; FORMOTEROL; INDACATEROL; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DYSPNEA; EVALUATION; HEALTH STATUS; HUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; ST GEORGE RESPIRATORY QUESTIONNAIRE; SYSTEMATIC REVIEW; TRANSITION DYSPNOEA INDEX; TREATMENT DURATION;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; ALBUTEROL; DOUBLE-BLIND METHOD; DYSPNEA; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMANS; INDANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES;

EID: 79955470155     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2011.02.013     Document Type: Article

References (35)

1. P.W. Jones Activity limitation and quality of life in COPD COPD 4 2007 273 278 (Pubitemid 47345894)
2. R. Dahl, L.A. Greefhorst, D. Nowak, V. Nonikov, A.M. Byrne, and M.H. Thomson Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease Am J Respir Crit Care Med 164 2001 778 784 (Pubitemid 32881913)
3. D.A. Mahler The effect of inhaled beta2-agonists on clinical outcomes in chronic obstructive pulmonary disease J Allergy Clin Immunol 110 6 Suppl. 2002 S298 S303
4. R.G. Barr, J. Bourbeau, C.A. Camargo, and F.S. Ram Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis Thorax 61 2006 854 862 [Erratum in: Thorax 2007;62:191] (Pubitemid 44570305)
5. M. Cazzola, M.G. Matera, and J. Lötvall Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease Expert Opin Investig Drugs 14 2005 775 783 (Pubitemid 41030946)
6. R. Dahl, K.F. Chung, R. Buhl, H. Magnussen, V. Nonikov, and D. Jack Efficacy of a new once-daily LABA, indacaterol, versus the twice-daily LABA, formoterol, in COPD Thorax 65 2010 473 479
7. J.F. Donohue, C. Fogarty, J. Lötvall, D.A. Mahler, H. Worth, and A. Yorganciolu Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium Am J Respir Crit Care Med 182 2010 155 162
8. O. Kornmann, R. Dahl, S. Centanni, A. Dogra, R. Owen, and C. Lassen Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparison Eur Respir J 37 2011 273 279
9. G. Feldman, T. Siler, N. Prasad, D. Jack, S. Piggott, R. Owen for the INLIGHT1 Study Group Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study BMC Pulm Med 10 2010 11
10. P.W. Jones, and A.G. Agusti Outcomes and markers in the assessment of chronic obstructive pulmonary disease Eur Respir J 27 2006 822 832 (Pubitemid 44914209)
11. D.A. Mahler, D.H. Weinberg, C.K. Wells, and A.R. Feinstein The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes Chest 85 1984 751 758 (Pubitemid 14121920)
12. P.W. Jones, F.H. Quirk, C.M. Baveystock, and P. Littlejohns A self-complete measure of health status for chronic airflow limitation. The St. George's respiratory questionnaire Am Rev Respir Dis 145 1992 1321 1327
13. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2005. At: http://www.goldcopd.com/GuidelineItem.asp? intId=1386.
14. D.A. Mahler, and T.J. Witek Jr. The MCID of the transition dyspnea index is a total score of one unit COPD 2 2005 99 103 (Pubitemid 40776229)
15. T.J. Witek Jr., and D.A. Mahler Meaningful effect size and patterns of response of the transition dyspnea index J Clin Epidemiol 56 2003 248 255 (Pubitemid 36513486)
16. T.J. Witek Jr., and D.A. Mahler Minimal important difference of the transition dyspnoea index in a multinational clinical trial Eur Respir J 21 2003 267 272 (Pubitemid 36204541)
17. P.W. Jones St. George's respiratory questionnaire: MCID COPD 2 2005 75 79 (Pubitemid 40776227)
18. D.A. Mahler Mechanisms and measurement of dyspnea in chronic obstructive pulmonary disease Proc Am Thorac Soc 3 2006 234 238 (Pubitemid 43668187)
19. P.W. Jones, S. Lareau, and D.A. Mahler Measuring the effects of COPD on the patient Respir Med 99 2005 511 518
20. P.W. Jones Health status measurement in chronic obstructive pulmonary disease Thorax 56 2001 880 887 (Pubitemid 32999838)
21. M. Cazzola, W. MacNee, F.J. Martinez, K.F. Rabe, L.G. Franciosi, and P.J. Barnes Outcomes for COPD pharmacological trials: from lung function to biomarkers Eur Respir J 31 2008 416 469
22. R. Casaburi, D.A. Mahler, P.W. Jones, A. Wanner, P.G. San, and R.L. ZuWallack A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease Eur Respir J 19 2002 217 224 (Pubitemid 34162820)
23. V. Brusasco, R. Hodder, M. Miravitlles, L. Korducki, L. Towse, and S. Kesten Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD Thorax 58 2003 399 404 [Erratum in: Thorax 2005;60:105] (Pubitemid 36560942)
24. J.F. Donohue, J.A. van Noord, E.D. Bateman, S.J. Langley, A. Lee, and T.J. Witek Jr. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol Chest 122 2002 47 55 (Pubitemid 34754142)
25. D.A. Mahler, J.F. Donohue, R.A. Barbee, M.D. Goldman, N.J. Gross, and M.E. Wisniewski Efficacy of salmeterol xinafoate in the treatment of COPD Chest 115 1999 957 965 (Pubitemid 29193661)
26. N.A. Hanania, P. Darken, D. Horstman, C. Reisner, B. Lee, and S. Davis The efficacy and safety of fluticasone propionate (250 μg)/salmeterol (50 μg) combined in the Diskus inhaler for the treatment of COPD Chest 124 2003 834 843 (Pubitemid 37123298)
27. R.L. ZuWallack, D.A. Mahler, D. Reilly, N. Church, A. Emmett, and K. Rickard Salmeterol plus theophylline combination therapy in the treatment of COPD Chest 119 2001 1661 1670 (Pubitemid 32744919)
28. P. Calverley, R. Pauwels, J. Vestbo, P. Jones, N. Pride, and A. Gulsvik Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial Lancet 361 2003 449 456 [Erratum: Lancet 2003;361:1660] (Pubitemid 36173708)
29. P.W. Jones, and T.K. Bosh Changes in quality of life in COPD patients treated with salmeterol Am J Respir Crit Care Med 155 1997 1283 1289 (Pubitemid 27172772)
30. R.A. Stockley, N. Chopra, and L. Rice Addition of salmeterol to existing treatment in patients with COPD: a 12 month study Thorax 61 2006 122 128 (Pubitemid 43235428)
31. D.A. Mahler, J. Ward, L.A. Waterman, C. McCusker, R. Zuwallack, and J.C. Baird Patient-reported dyspnea in COPD reliability and association with stage of disease Chest 136 2009 1473 1479
32. M. Williams, P. Cafarella, T. Olds, J. Petkov, and P. Frith Affective descriptors of the sensation of breathlessness are more highly associated with severity of impairment than physical descriptors in people with chronic obstructive pulmonary disease Chest 138 2010 315 322
33. M. Williams, P. Cafarella, T. Olds, J. Petkov, and P. Frith The language of breathlessness differentiates between patients with COPD and age-matched adults Chest 134 2008 489 496
34. P.M.A. Calverley, S. Spencer, L.R. Willits, P.S. Burge, and P.W. Jones Withdrawal from treatment as an outcome in the ISOLDE study of COPD Chest 124 2003 1350 1356 (Pubitemid 37290045)
35. J.A. Wedzicha, P.M. Calverley, T.A. Seemungal, G. Hagan, Z. Ansari, and R.A. Stockley The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide Am J Respir Crit Care Med 177 2008 19 26